AU2002247977C1 - HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases - Google Patents
HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases Download PDFInfo
- Publication number
- AU2002247977C1 AU2002247977C1 AU2002247977A AU2002247977A AU2002247977C1 AU 2002247977 C1 AU2002247977 C1 AU 2002247977C1 AU 2002247977 A AU2002247977 A AU 2002247977A AU 2002247977 A AU2002247977 A AU 2002247977A AU 2002247977 C1 AU2002247977 C1 AU 2002247977C1
- Authority
- AU
- Australia
- Prior art keywords
- hmgb1
- cells
- box
- hmg
- rsmc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000019553 vascular disease Diseases 0.000 title claims abstract description 10
- 108700010013 HMGB1 Proteins 0.000 title claims description 161
- 239000005557 antagonist Substances 0.000 title claims description 11
- 102000055207 HMGB1 Human genes 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 title abstract description 14
- 239000012268 protein inhibitor Substances 0.000 title description 3
- 229940121649 protein inhibitor Drugs 0.000 title description 3
- 229940076372 protein antagonist Drugs 0.000 title description 2
- 230000027455 binding Effects 0.000 claims abstract description 12
- 101150021904 HMGB1 gene Proteins 0.000 claims description 155
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 153
- 238000000034 method Methods 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 210000002808 connective tissue Anatomy 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 238000002399 angioplasty Methods 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 206010052428 Wound Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 claims description 3
- 101001061840 Homo sapiens Advanced glycosylation end product-specific receptor Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 102100037907 High mobility group protein B1 Human genes 0.000 description 154
- 210000004027 cell Anatomy 0.000 description 85
- 230000012292 cell migration Effects 0.000 description 22
- 238000013508 migration Methods 0.000 description 22
- 230000005012 migration Effects 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 230000004044 response Effects 0.000 description 16
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004292 cytoskeleton Anatomy 0.000 description 15
- 230000035605 chemotaxis Effects 0.000 description 14
- 230000003993 interaction Effects 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 12
- 230000008521 reorganization Effects 0.000 description 12
- 108010081690 Pertussis Toxin Proteins 0.000 description 11
- 239000002975 chemoattractant Substances 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 108091006027 G proteins Proteins 0.000 description 7
- 102000030782 GTP binding Human genes 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 230000001617 migratory effect Effects 0.000 description 7
- 230000001338 necrotic effect Effects 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 210000003518 stress fiber Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000034354 Gi proteins Human genes 0.000 description 4
- 108091006101 Gi proteins Proteins 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 4
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003632 microfilament Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 108700004921 tetramethylrhodaminylphalloidine Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 101100178203 Arabidopsis thaliana HMGB3 gene Proteins 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 101710089384 Extracellular protease Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101150091750 HMG1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000008378 epithelial damage Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000033885 plasminogen activation Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004231 tunica media Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010002023 Amyloidoses Diseases 0.000 description 1
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000010002 chemokinesis Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229940084430 four-way Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000000280 pituicyte Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- TXBNDGDMWKVRQW-UHFFFAOYSA-M sodium;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]acetate;dodecyl sulfate Chemical compound [Na+].OCC(CO)(CO)NCC(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O TXBNDGDMWKVRQW-UHFFFAOYSA-M 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000562A ITMI20010562A1 (it) | 2001-03-16 | 2001-03-16 | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| ITMI2001A000562 | 2001-03-16 | ||
| PCT/IT2002/000153 WO2002074337A1 (en) | 2001-03-16 | 2002-03-12 | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
Publications (5)
| Publication Number | Publication Date |
|---|---|
| AU2002247977A1 AU2002247977A1 (en) | 2002-10-03 |
| AU2002247977A2 AU2002247977A2 (en) | 2004-02-26 |
| AU2002247977B2 AU2002247977B2 (en) | 2006-12-14 |
| AU2002247977B8 AU2002247977B8 (en) | 2007-03-15 |
| AU2002247977C1 true AU2002247977C1 (en) | 2008-09-18 |
Family
ID=11447291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002247977A Ceased AU2002247977C1 (en) | 2001-03-16 | 2002-03-12 | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7754217B2 (enExample) |
| EP (1) | EP1368060B1 (enExample) |
| JP (1) | JP4822654B2 (enExample) |
| CN (2) | CN1537014B (enExample) |
| AT (1) | ATE468137T1 (enExample) |
| AU (1) | AU2002247977C1 (enExample) |
| CA (1) | CA2439530C (enExample) |
| DE (1) | DE60236413D1 (enExample) |
| DK (1) | DK1368060T3 (enExample) |
| ES (1) | ES2346408T3 (enExample) |
| IT (1) | ITMI20010562A1 (enExample) |
| MX (1) | MXPA03008364A (enExample) |
| PT (1) | PT1368060E (enExample) |
| WO (1) | WO2002074337A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| HUP0500042A3 (en) * | 2001-05-15 | 2010-01-28 | Long Island Jewish Res Inst | Use of hmg fragments as anti-inflammatory agents |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| ATE424416T1 (de) | 2002-07-03 | 2009-03-15 | San Raffaele Centro Fond | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| WO2004061456A2 (de) * | 2003-01-03 | 2004-07-22 | Alcedo Biotech Gmbh | Verwendungen von hmgb, hmgn, hmga proteinen |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| ITRM20040058A1 (it) * | 2004-02-03 | 2004-05-03 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali. |
| PT1768677E (pt) * | 2004-07-02 | 2008-10-06 | Creabilis Therapeutics Spa | Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1 |
| US20090062187A1 (en) | 2004-07-20 | 2009-03-05 | Marco Bianchi | Use of Hmgb1 for Wound Healing |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| EP1797118A2 (en) * | 2004-09-03 | 2007-06-20 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
| WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
| ITRM20050032A1 (it) * | 2005-01-21 | 2006-07-22 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica. |
| WO2006114805A2 (en) * | 2005-04-28 | 2006-11-02 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb2 and hmgb3 proteins for medical applications |
| US20100040608A1 (en) | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
| AU2006284096B2 (en) | 2005-08-25 | 2012-03-29 | Avro Life Sciences, Inc. | Polymer conjugates of K-252a and derivatives thereof |
| WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
| CA2631212A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
| US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
| CA2663300C (en) | 2006-09-15 | 2014-10-07 | Creabilis Therapeutics S.P.A. | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
| US8470325B2 (en) | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
| RU2519714C2 (ru) | 2008-04-30 | 2014-06-20 | Дженомикс Ко., Лтд. | Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток |
| WO2009133943A1 (ja) | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
| JP5582580B2 (ja) * | 2009-07-16 | 2014-09-03 | Ｎｅｃソリューションイノベータ株式会社 | Ｈｍｇｂ１結合核酸分子およびその用途 |
| JP5467313B2 (ja) * | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
| CN102711777B (zh) | 2009-10-28 | 2015-04-15 | 吉诺米克斯股份有限公司 | 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂 |
| CA2847197C (en) | 2010-10-30 | 2020-11-03 | Isis Innovation Limited | Treatment for dupuytren's disease |
| DK2703487T3 (en) | 2011-04-26 | 2018-09-10 | Genomix Co Ltd | TIME TO INDUCTION Tissue Regeneration and its Use |
| US9244074B2 (en) * | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| RU2647467C2 (ru) | 2012-10-25 | 2018-03-15 | Дженомикс Ко., Лтд. | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 |
| EP2913059B1 (en) | 2012-10-25 | 2018-04-11 | Genomix Co., Ltd. | Novel method for treating spinal cord injury using hmgb1 fragment |
| MX2015009547A (es) | 2013-01-28 | 2015-11-25 | Evec Inc | Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo. |
| IL242807A0 (en) * | 2015-11-26 | 2016-04-21 | Novamed Ltd | Test facility |
| US11274132B2 (en) | 2015-12-11 | 2022-03-15 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of PKM2 modulators and HMGB1 |
| BR112019014921A2 (pt) | 2017-01-27 | 2020-03-31 | StemRIM Inc. | Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica |
| EP3719117A4 (en) | 2017-12-01 | 2021-11-03 | Stemrim Inc. | EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM |
| US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
| US20210024594A1 (en) | 2018-02-08 | 2021-01-28 | StemRIM Inc. | Therapeutic Agent for Psoriasis |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| CN115361966B (zh) * | 2020-04-22 | 2025-09-16 | 朱拉隆功大学 | 使dna恢复活力和防止dna损伤的组合物以及方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997039125A1 (en) * | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft Patente | Antibodies against the advanced glycosylation end-product receptor and uses thereof |
| WO1997039121A1 (en) * | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| WO1998022138A1 (en) * | 1996-11-22 | 1998-05-28 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| WO2000047104A2 (en) * | 1999-02-11 | 2000-08-17 | North Shore-Long Island Jewish Research Institute | Antagonists of hmg1 for treating inflammatory conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US5470307A (en) * | 1994-03-16 | 1995-11-28 | Lindall; Arnold W. | Catheter system for controllably releasing a therapeutic agent at a remote tissue site |
| WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
| US6398808B1 (en) | 1999-06-15 | 2002-06-04 | Scimed Life Systems, Inc. | Localized delivery of genetic information from biostable materials |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| HUP0500042A3 (en) * | 2001-05-15 | 2010-01-28 | Long Island Jewish Res Inst | Use of hmg fragments as anti-inflammatory agents |
| ITRM20040058A1 (it) * | 2004-02-03 | 2004-05-03 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali. |
| US20090062187A1 (en) * | 2004-07-20 | 2009-03-05 | Marco Bianchi | Use of Hmgb1 for Wound Healing |
| WO2008137552A2 (en) * | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
-
2001
- 2001-03-16 IT IT2001MI000562A patent/ITMI20010562A1/it unknown
- 2001-03-16 US US10/471,641 patent/US7754217B2/en not_active Expired - Fee Related
-
2002
- 2002-03-12 EP EP02717057A patent/EP1368060B1/en not_active Expired - Lifetime
- 2002-03-12 CN CN028065670A patent/CN1537014B/zh not_active Expired - Fee Related
- 2002-03-12 AU AU2002247977A patent/AU2002247977C1/en not_active Ceased
- 2002-03-12 DK DK02717057.0T patent/DK1368060T3/da active
- 2002-03-12 CN CN200910252323A patent/CN101773669A/zh active Pending
- 2002-03-12 ES ES02717057T patent/ES2346408T3/es not_active Expired - Lifetime
- 2002-03-12 CA CA2439530A patent/CA2439530C/en not_active Expired - Fee Related
- 2002-03-12 MX MXPA03008364A patent/MXPA03008364A/es active IP Right Grant
- 2002-03-12 AT AT02717057T patent/ATE468137T1/de active
- 2002-03-12 DE DE60236413T patent/DE60236413D1/de not_active Expired - Lifetime
- 2002-03-12 JP JP2002573044A patent/JP4822654B2/ja not_active Expired - Fee Related
- 2002-03-12 PT PT02717057T patent/PT1368060E/pt unknown
- 2002-03-12 WO PCT/IT2002/000153 patent/WO2002074337A1/en not_active Ceased
-
2008
- 2008-01-02 US US11/968,506 patent/US8058239B2/en not_active Expired - Fee Related
-
2010
- 2010-02-17 US US12/707,222 patent/US20100172896A1/en not_active Abandoned
- 2010-02-17 US US12/707,264 patent/US20100297107A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997039125A1 (en) * | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft Patente | Antibodies against the advanced glycosylation end-product receptor and uses thereof |
| WO1997039121A1 (en) * | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| WO1998022138A1 (en) * | 1996-11-22 | 1998-05-28 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| WO2000047104A2 (en) * | 1999-02-11 | 2000-08-17 | North Shore-Long Island Jewish Research Institute | Antagonists of hmg1 for treating inflammatory conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1537014B (zh) | 2012-04-25 |
| JP2004523579A (ja) | 2004-08-05 |
| AU2002247977B8 (en) | 2007-03-15 |
| WO2002074337A1 (en) | 2002-09-26 |
| AU2002247977B2 (en) | 2006-12-14 |
| US20100297107A1 (en) | 2010-11-25 |
| DK1368060T3 (da) | 2010-08-30 |
| ES2346408T3 (es) | 2010-10-15 |
| EP1368060A1 (en) | 2003-12-10 |
| EP1368060B1 (en) | 2010-05-19 |
| AU2002247977A2 (en) | 2004-02-26 |
| ITMI20010562A1 (it) | 2002-09-16 |
| DE60236413D1 (de) | 2010-07-01 |
| US8058239B2 (en) | 2011-11-15 |
| US7754217B2 (en) | 2010-07-13 |
| US20100172896A1 (en) | 2010-07-08 |
| PT1368060E (pt) | 2010-08-24 |
| HK1069316A1 (en) | 2005-05-20 |
| CA2439530C (en) | 2016-11-08 |
| AU2002247977A1 (en) | 2002-10-03 |
| MXPA03008364A (es) | 2004-11-12 |
| US20080171052A1 (en) | 2008-07-17 |
| US20040136979A1 (en) | 2004-07-15 |
| CN1537014A (zh) | 2004-10-13 |
| ATE468137T1 (de) | 2010-06-15 |
| CA2439530A1 (en) | 2002-09-26 |
| CN101773669A (zh) | 2010-07-14 |
| WO2002074337A8 (en) | 2003-08-28 |
| JP4822654B2 (ja) | 2011-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002247977C1 (en) | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
| Degryse et al. | The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells | |
| Moura-da-Silva et al. | Jararhagin, a hemorrhagic snake venom metalloproteinase from Bothrops jararaca | |
| Chen et al. | Interleukin-17 induces angiogenesis in human choroidal endothelial cells in vitro | |
| JPH01135724A (ja) | 非特異的炎症の治療法 | |
| JPH10505086A (ja) | Ｓｅｃ受容体のブロッキング方法 | |
| EP1817327A1 (en) | Antigenic epitopes of interleukin-21, related antibodies and their use in medical field | |
| Ambort et al. | Specific processing of tenascin-C by the metalloprotease meprinβ neutralizes its inhibition of cell spreading | |
| Wary et al. | Anti-lipid phosphate phosphohydrolase-3 (LPP3) antibody inhibits bFGF-and VEGF-induced capillary morphogenesis of endothelial cells | |
| Konishi et al. | N-terminal cleaved pancreatitis-associated protein-III (PAP-III) serves as a scaffold for neurites and promotes neurite outgrowth | |
| US7824868B2 (en) | Formation of superfibronectin by BBK32 and uses therefor | |
| WO2011092294A1 (en) | Extracellular ifi16 as therapeutic agents | |
| JP2006516024A (ja) | α１β１インテグリンの誘導性リガンドおよび使用 | |
| HK1146703A (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
| HK1069316B (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
| US9382322B2 (en) | Tissue repair by modulation of beta-1 integrin biological function | |
| Bogatkevich et al. | Dabigatran, a direct thrombin inhibitor, blocks differentiation of normal fibroblasts to a myofibroblast phenotype and demonstrates anti-fibrotic effects on scleroderma lung fibroblasts | |
| JP2000505643A (ja) | レクチン様性質を有する化合物およびその生物学的応用 | |
| Das et al. | Evidence for binding of the ectodomain of amyloid precursor protein 695 and activated high molecular weight kininogen | |
| ES2362655T3 (es) | Métodos y composiciones para suprimir la diferenciación de fibrocitos. | |
| Héry-Huynh et al. | Induction and regulation of murine emphysema by elastin peptides 2 | |
| Khunkaewla | Doktorln der Medizinischen Wissenschaft | |
| JPH08511941A (ja) | ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2003 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JAN 2004 |
|
| TH | Corrigenda |
Free format text: IN VOL 20, NO 48, PAGE(S) 4879 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BIO3 RESEARCH S.R.L., APPLICATION NO. 2002247977, UNDER INID (71) INSERT THE NAME BIANCHI, M. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 FEB 2008. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 FEB 2008 |
|
| PC | Assignment registered |
Owner name: BIO3 RESEARCH S.R.L. Free format text: FORMER OWNER WAS: BIANCHI, MARCO; BIO3 RESEARCH S.R.L. |
|
| GM | Mortgages registered |
Name of requester: BIANCHI, M. |
|
| GMD | Discharge of a mortgage |
Effective date: 20120313 |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |